Abstracts tagged "inflammation and macrophage activation syndrome"

Abstract Number: 1417 • 2018 ACR/ARHP Annual Meeting
Hemophagocytic Lymphohistiocytosis (HLH) Mimickers: CXCL9 As a Potential Biomarker Distinguishing HLH from Other Hyperferritinemic Syndromes
Giulia Marucci¹, Ivan Caiello², Manuela Pardeo¹, Virginia Messia¹, Giusi Prencipe¹, Antonia Pascarella¹, Fabrizio De Benedetti³ and Claudia Bracaglia¹, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ³IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
Background/Purpose: Increased ferritin is considered biomarker highly suggestive of primary and secondary HLH and it is one of the HLH-2004 diagnostic and MAS guidelines (1,2),…
Abstract Number: 1402 • 2015 ACR/ARHP Annual Meeting
Development of Systemic Juvenile Idiopathic Arthritis Manifestations Following Remission of Hemophagocytic Lymphohistiocytosis
Baruch Goldberg¹, Eyal Muscal², Marietta De Guzman³ and Carl Allen⁴, ¹Pediatric Rheumatology, Texas Children's Hospital, Houston, TX, ²Pediatric Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Pediatric Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁴Pediatric Hematology and Oncology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a potentially fatal pathologic inflammatory process resulting from impaired immune function due to inherited gene mutations or secondary to…
Abstract Number: 1058 • 2012 ACR/ARHP Annual Meeting
Fulminant Toll-Like Receptor 9-Induced Macrophage Activation Syndrome and Hemophagocytosis Occur Independently of Interferon Gamma
Scott W. Canna¹, Julia Wrobel², Portia A. Kreiger³, Michele E. Paessler⁴ and Edward M. Behrens⁵, ¹Pediatric Rheumatology, Childrens Hospital of Philadelphia, Philadelphia, PA, ²Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ³Pathology, Nemours/A.I. DuPont Hospital for Children, Wilmington, DE, ⁴Hematopathology, Childrens Hospital of Philadelphia, Philadelphia, PA, ⁵Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Macrophage Activation Syndrome (MAS) is a potentially lethal cytokine storm syndrome that complicates various rheumatic diseases. We have previously shown that Toll-like Receptor (TLR9)…
Abstract Number: 1074 • 2012 ACR/ARHP Annual Meeting
TLR2 Deletion Promotes Arthritis and Joint Destruction Through Reduction of IL-10
Qi Quan Huang¹, Renee E. Koessler¹, Robert Birkett², Harris R. Perlman³, Lianping Xing⁴ and Richard M. Pope⁵, ¹Medicine/Rheumatology, Northwestern University, Chicago, IL, ²Division of Rheumatology, Department od Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Feinberg School of Medicine, Northwestern University, Chicago, IL, ⁴Pathology & Lab Medicine, University of Rochester, Rochester, NY, ⁵Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL
Background/Purpose: TLR2 signaling pathway has been suggested as a potential therapeutic target in RA. However, studies with mice deficient in TLR2 (TLR2-/-) and IL-1Ra suggest…
Abstract Number: 903 • 2012 ACR/ARHP Annual Meeting
NR4A1 Mediates Anti-Inflammatory Effects of Apoptotic Cells
Natacha Ipseiz¹, Stefan Uderhardt¹, Georg A. Schett² and Gerhard Kronke¹, ¹Internal Medicine 3, University of Erlangen, Erlangen, Germany, ²Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: The nuclear receptor NR4A1 has been implicated as negative feedback regulator of NF kappa B signalling and as key regulator during the differentiation of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].